| Chronic Obstructive Airway Disease
Incruse Ellipta vs Ohtuvayre
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Incruse Ellipta vs Ohtuvayre with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOhtuvayre has a higher rate of injection site reactions vs Incruse Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ohtuvayre but not Incruse Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Incruse Ellipta
Ohtuvayre
At A Glance
Oral inhalation
Once daily
Long-acting muscarinic antagonist
Oral inhalation
Twice daily
PDE3/PDE4 inhibitor
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation; use at the same time every day; do not use more than 1 time every 24 hours. No dosage adjustment required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
Chronic Obstructive Airway Disease 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, via oral inhalation using a standard jet nebulizer with a mouthpiece.
Contraindications
- Severe hypersensitivity to milk proteins
- Hypersensitivity to umeclidinium or any of the excipients
- Hypersensitivity to ensifentrine or any component of this product
Adverse Reactions
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, cough, arthralgia, pharyngitis, viral upper respiratory tract infection, myalgia, abdominal pain upper, toothache, contusion, tachycardia
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Eye pain, glaucoma, vision blurred, anaphylaxis, angioedema, pruritus, urticaria, dysuria, urinary retention, dysphonia, oropharyngeal pain
Most common (>=1%) Back pain, hypertension, urinary tract infection, diarrhea
Serious Paradoxical bronchospasm, psychiatric events including suicidality
Pharmacology
Long-acting muscarinic antagonist (LAMA/anticholinergic); competitively and reversibly inhibits M3 receptors at airway smooth muscle to produce bronchodilation lasting longer than 24 hours after once-daily oral inhalation.
Ensifentrine is a dual inhibitor of PDE3 and PDE4 enzymes; inhibition results in accumulation of intracellular cAMP and/or cGMP, producing downstream bronchodilatory and anti-inflammatory signaling effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Incruse Ellipta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Ohtuvayre
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Incruse Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Ohtuvayre
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Incruse Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Ohtuvayre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Incruse Ellipta.
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Incruse ElliptaView full Incruse Ellipta profile
OhtuvayreView full Ohtuvayre profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.